Pregnancy claims
FDA will hold a public meeting March 30 on safety issues related to dietary supplement use during pregnancy. In a notice to be published in the Feb. 24 Federal Register, FDA seeks comments on five points: potential maternal and fetal hazards associated with supplement use for pregnancy-related conditions; existence of certain pregnancy-related conditions for which structure/function claims should be permitted; potential harm of using supplements during pregnancy for conditions unrelated to pregnancy; means of addressing safety concerns associated with supplement use during pregnancy; and use of specific warnings on supplements for pregnancy-related conditions. The meeting is 9 a.m. to 5 p.m. at the Hilton in Gaithersburg, Md.; comments are due within 60 days of the Federal Register notice date
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
In an unusual move, Tracy Beth Høeg, a special assistant to FDA Commissioner Martin Makary, is leading the continued negotiations on Novavax’s delayed COVID-19 vaccine approval.
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.